Contents
Download PDF
pdf Download XML
847 Views
166 Downloads
Share this article
Research Article | Volume 4 Issue 2 (July-Dec, 2023) | Pages 1 - 4
Levels of Studied Biomarkers in Metastatic Prostate Cancer Patients
 ,
 ,
1
Department of Pathological analyses, College of Science, University of kufa, Najaf, Iraq
2
Department of biology, college of science, University of Kufa, Najaf, lraq
Under a Creative Commons license
Open Access
Received
May 6, 2023
Revised
June 7, 2023
Accepted
July 18, 2023
Published
Aug. 9, 2023
Abstract

Prostate cancer, a prevalent malignancy in males, often exhibits metastatic tendencies, particularly to bone. This study aimed to investigate the levels of selected biomarkers, including Alkaline Phosphatase (ALP) and serum lipid profile components, in metastatic prostate cancer patients. Blood samples were collected from male patients aged 50-70 with metastatic prostate cancer at Al-Furat Al-Awsat Oncology Hospital between 1/11/2021 and 15/1/2022. Biomarker levels were quantified using standardized assays. The results revealed elevated concentrations of ALP, total cholesterol, and triglycerides, accompanied by reduced levels of low-density lipoprotein (LDL) in the blood of metastatic prostate cancer patients compared to healthy controls. These findings underscore the potential role of these biomarkers in reflecting the pathophysiological changes associated with metastatic prostate cancer. The significance of these alterations in disease progression and potential implications for diagnostic and therapeutic strategies warrant further investigation.

Keywords
INTRODUCTION

The prostate gland, derived from the Greek word "Prohistani," is the largest accessory sex gland in males, playing a crucial role in reproduction. It secretes alkaline fluid, constituting a significant portion of seminal fluid volume. Alterations in prostatic fluid composition can impact sperm function and male fertility. The gland is often linked to disorders such as Benign Prostatic Hyperplasia (BPH) and carcinoma, particularly in older individuals .[1]The structure of the prostate gland is a complex amalgamation of glandular and fibromuscular tissue arranged in distinct anatomical zones. It resides within the pelvic cavity, enveloped by internal and external connective tissue capsules. The prostate's function in facilitating healthy semen, ideal for sperm survival and transit, underscores its importance in reproduction. The gland's growth is regulated by testosterone and dihydrotestosterone, with testosterone primarily produced in the testes .[3]Prostate cancer, the most common malignancy in men globally, is characterized by the mutation of prostate gland cells into cancerous cells. It often spreads to bones and lymph nodes, posing significant health risks. The genetic mutations and alterations in signaling pathways contribute to its pathophysiology [4]. This article delves into various aspects of the prostate gland, prostate cancer, risk factors, diagnostic parameters, and the implications of serum lipid profiles. The study aims to investigate the role of Alkaline Phosphatase (ALP) as a biochemical marker in metastatic prostate cancer patients, explore the relationship between lipid profiles and metastatic prostate cancer, and elucidate the stage of prostate cancer progression, particularly its bone involvement. The genesis of prostate cancer involves uncontrolled growth of prostate gland cells, resulting in tumor formation. Malignant tumors have the potential to spread through metastasis via the bloodstream or lymphatic system. Regional lymph nodes are frequently among the first sites of metastasis, followed by bones, lungs, and liver. Notably, metastatic prostate cancer can be effectively treated in many cases, allowing for extended periods of healthy living [5]. Age, race, family history, and lifestyle factors significantly impact the risk of developing prostate cancer. Advancing age and a family history of the disease elevate susceptibility. Lifestyle elements such as obesity and diet also play a role [6]. Diagnostic methods for prostate cancer include the prostate-specific antigen blood test, digital rectal examination, biopsy, MRI, and CT scans. PSA levels, Gleason score, and imaging techniques aid in diagnosis, staging, and treatment planning [7]. The introduction of PSA testing has led to increased prostate cancer diagnoses, but overdiagnosis is a concern. Screening's impact on mortality varies, and treatments can lead to complications. Informed decision-making is crucial for individuals considering screening [8]. The relationship between lipid profile components (total cholesterol, LDL, HDL, triglycerides) and prostate cancer is complex. Cholesterol's role in cancer development and the influence of lipids on cancer severity are subjects of investigation [9].

 

Aims of Study

The study aims to achieve the following objectives:

 

  • Investigate the role of Alkaline phosphatase (ALP) as a biochemical marker in metastatic prostate cancer patients

  • Explore the relationship between lipid profile components and metastatic prostate cancer

  • Determine the stage of prostate cancer, with a focus on bone metastasis

MATERIALS AND METHODS

Blood Collection

Blood serum samples were obtained from male patients aged 50 to 70 years who were admitted to Al-Furat Al-Awsat Oncology Hospital. The collection period spanned from November 1, 2021, to January 15, 2022 [10].

 

Methods

Procedure of Alp: The Alkaline Phosphatase (Alp) procedure commenced by adding Buffered Substrate pH-10 as follows: 0.5 mL for Blank, 0.5 mL for Standard, and 0.5 mL for Test. Subsequently, distilled water (D/W) was incorporated in quantities of 1.55 mL for Blank, 1.55 mL for Standard, and 1.55 mL for Test. The mixture was thoroughly combined and allowed to incubate at a temperature of 37°C for a duration of 15 minutes. For Blank, Standard, and Test samples, Serum was introduced: 50 micro L for Standard and 50 micro L for Test. Additionally, Phenol STD was added in quantities of 50 micro L for Standard. The mixture was once again mixed and incubated at 37°C for another 15 minutes. For the final phase of color development, colored reagent consisting of 4 aminoantipyrine and potassium ferricyanide was added: 1 mL for Blank, 1 mL for Standard, and 1 mL for Test. The mixture was thoroughly mixed and its absorbance was read at 520 nm. To determine Alkaline phosphatase (Alp) activity, the following formula was employed: Alp = (Absorbance of sample/Absorbance of standard) × concentration of standard.

 

Procedure of TG

For the determination of triglyceride (TG) concentration, the procedure involved setting the wavelength to 505 nm within the range of 490-550 nm, while maintaining a temperature of 37°C/15-25°C. The cuvette path length was standardized to 1 cm. Prior to sample analysis, the instrument was zeroed using distilled water. Cuvettes were then prepared, comprising 10 micro L of standard, 10 micro L of test sample, and 1 mL of the working reagent. Following the preparation, the mixture was incubated for 5 minutes at 37°C or 10 minutes at room temperature. Subsequently, the absorbance was measured against a blank. The concentration of triglyceride (TG) was determined using the formula: TG = (Absorbance of sample/Absorbance of standard) × concentration of standard [11].

 

Procedure of Cholesterol

For the cholesterol procedure, cuvettes were set up with the following components: 1 mL of working reagent, 10 micro L of blank, 10 micro L of specimen (sample), and 10 micro L of standard. The prepared cuvettes were then incubated for 10 minutes at room temperature or 5 minutes at 37°C. Subsequently, absorbance readings were taken against the reagent blank. The total cholesterol concentration was determined by applying the formula: Total cholesterol = (Absorbance of sample/Absorbance of standard) × concentration of standard (12).

 

Procedure of HDL, LDL, VLDL

For the determination of HDL, LDL, and VLDL concentrations, 500 micro L of serum was mixed with 50 micro L of cholesterol reagent and allowed to incubate for 15 minutes. Following incubation, centrifugation was carried out to remove lipid complexes. Subsequently, 1 mL of HDL reagent was added to 25 micro L of the supernatant and incubated for 5 minutes. The resulting mixture was subjected to absorbance measurement using a spectrophotometer at 600 nm. The normal value for HDL was considered to be greater than 35 mg/dL (0.9 mmol/L). The concentrations of HDL, VLDL, and LDL were determined through the following calculations: HDL concentration was calculated as (Absorbance of sample / Absorbance of standard) multiplied by the concentration of the standard. VLDL concentration was calculated as TG divided by 5, and LDL concentration was determined as the difference between the total cholesterol and the sum of HDL and VLDL concentrations [13].

RESULTS AND DISCUSSION

The presence of prostate cancer, and its potential spread to the bones, triggers a breakdown of bone and tissue in affected areas, leading to an elevated release of alkaline phosphatase (ALP) into the bloodstream. Statistical analysis, utilizing the T-Test, was conducted to compare the mean ALP activity in the blood of prostate cancer patients to that of healthy individuals, and the results are summarized in Table 1 [14].

 

Table 1:ALP Activity in The Blood of Prostate

Mean131.9
Std. Deviation77.14
Std. Error of Mean17.70
Lower 95% CL94.69
Upper 95% CL169.0

 

The obtained data undeniably demonstrated a significant increase in ALP activity within the blood of prostate cancer patients when compared to healthy controls (p <0.001, elevated). This finding is visually represented in Figure 1 [15].

 

 

 

Figure 1: ALP Activity in Prostate Cancer the Graph Illustrates Higher ALP Activity in Prostate Cancer Patients Compared to Healthy Individuals

 

Lipid Profile

Elevated blood lipid levels have been consistently associated with a higher risk of cancer-specific mortality and overall mortality in patients. To explore this connection, the mean concentration of Triglycerides (TG) in the blood of prostate cancer patients was compared to that of healthy subjects, and the outcomes are summarized in Table 2 [16].

 

Table 2: Triglycerides Concentration within the Blood

Mean299.4
Std. Deviation114.0
Std. Error of Mean26.15
Lower 95% CL244.4
Upper 95% CL354.3

 

The statistical analysis confirmed a substantial increase in TG concentration within the blood of individuals with prostate cancer in contrast to healthy individuals (p <0.001, elevated). This outcome is visually depicted in Figure 2 [17].

 

 

 

Figure 2: TG Concentration in Prostate Cancer the Graphical Representation Showcases Elevated TG Concentration in Prostate Cancer Patients Compared to Healthy Controls

 

Furthermore, the interplay between lipids and lipoproteins in relation to prostate and breast cancer has been a subject of significant exploration. To this end, the mean concentration of cholesterol in the blood of prostate cancer patients was compared to that of healthy controls, and the findings are summarized in Table 3 [18].

 

Table 3: Mean Concentration of Cholesterol

Mean192.5
Std. Deviation61.14
Std. Error of Mean14.03
Lower 95% CL163.0
Upper 95% CL221.9

 

The statistical analysis yielded compelling evidence of a marked elevation in cholesterol concentration within the blood of prostate cancer patients when contrasted with healthy individuals (p <0.001, elevated). This observation is visually elucidated in Figure 3.

 

 

 

Figure 3: Cholesterol Concentration in Prostate Cancer the Diagram Presents Heightened Cholesterol Concentration in Prostate Cancer Patients Compared to Healthy Controls

 

Low-Density Lipoprotein (LDL)

An examination of data preceding cancer diagnosis revealed that LDL cholesterol values tended to be lower in individuals diagnosed with cancer compared to matched control subjects. The mean concentration of LDL cholesterol in the blood of prostate cancer patients was compared to that of healthy individuals, and the results are summarized in Table 3.

 

Statistical analysis conclusively established a significant reduction in LDL cholesterol concentration within the blood of individuals with prostate cancer compared to healthy controls (p >0.001, lowered). This insight is visually portrayed in Table 4.

 

Table 4: LDL Concentration in Prostate Cancer the Chart Highlights Lower LDL Cholesterol Concentration in Prostate Cancer Patients Compared to Healthy Controls

Mean82.81
Std. Deviation53.52
Std. Error of Mean12.28
Lower 95% CL57.02
Upper 95% CL108.6

 

These results collectively underscore the intricate relationship between lipid metabolism and prostate cancer, suggesting that aberrations in lipid profiles, particularly elevated ALP, TG, and cholesterol concentrations, along with decreased LDL levels, may hold promise as potential biomarkers for prostate cancer. Further research is imperative to elucidate the underlying mechanisms of these lipid alterations and their precise role in prostate cancer development and progression.

CONCLUSION

A significant increase in ALP, TG, and cholesterol, and a significant decrease in LDL was spotted in the blood of a prostate cancer patients, which is agreed with previous studies, indicating that the alteration in these concentrations is associated with the development of prostate cancer, and the abnormal concentrations of these parameters may be a clef to the pathogenesis of prostate cancer.

REFERENCE
  1. Kumar, A. et al. Basics of Human Andrology. Springer Nature Singapore Pte Ltd, 2017. https://doi.org/10.

  2. Eroschenko, V., and M. Fiore. DiFiore’s Atlas of Histology with Functional Correlations. 11th ed., Wolters Kluwer Health/Lippincott Williams & Wilkins, 2008, pp. 428–431.

  3. TortoleroLuna, G. et al. Cancer in Puerto Rico, 2008–2012. Puerto Rico Central Cancer Registry, San Juan, 2013.

  4. Siegel, R. et al. “Cancer statistics, 2012.” CA: A Cancer Journal for Clinicians, vol. 62, 2012, pp. 10–29.

  5. Allott, E.H. et al. “Obesity and prostate cancer: Weighing the evidence.” European Urology, vol. 63, 2013, pp. 800–809.

  6. Solomon, K.R., and M.R. Freeman. “Do the cholesterol-lowering properties of statins affect cancer risk?” Trends in Endocrinology and Metabolism, vol. 19, 2008, pp. 113–121.

  7. Chu, D.I., and S.J. Freedland. “Metabolic risk factors in prostate cancer.” Cancer, vol. 117, 2011, pp. 2020–2023.

  8. Havel, R.J. “Postprandial hyperlipidemia and remnant lipoproteins.” Current Opinion in Lipidology, vol. 5, 1994, pp. 102–109.

  9. Pleton, K. et al. “Cholesterol and prostate cancer.” Current Opinion in Pharmacology, vol. 12, 2012, pp. 751–759.

  10. Li, D. et al. “Prognostic value of serum alkaline phosphatase in the survival of prostate cancer: Evidence from a meta-analysis.” Cancer Management and Research, vol. 10, 2018, pp. 3125–3139. 

  11. Alibraheemi, N.A.A. et al. “Effect of curcumin on lh and fsh hormones of polycystic syndrome induced by letrozole in female rats.” Latin American Journal of Pharmacy, vol. 40, 2021, pp. 179–183.

  12. Mahmoud, M. et al. “Study of hematological and biochemical changes in sheep and goats infected with theileriosis at Najaf province, Iraq.” Biochemical and Cellular Archives, vol. 19, no. 1, 2019, pp. 1863–1867.

  13. Al-Dhalimy, A.M.B. et al. “Study of the deficiency of some elements and some vital variables in camel’s blood.” Plant Archives, vol. 20, no. 2, 2020, pp. 8945–8949.

  14. Bustani, G.S. et al. “Protective effects of curcumin on testicular and sperm parameters abnormalities induced by nicotine in male rats.” AIP Conference Proceedings, vol. 2386, no. 1, Jan. 2022.

  15. Al-Hasan, B.A. et al. “First report of avian metapneumovirus type b in iraqi broiler flocks with swollen head syndrome.” Veterinary World, vol. 15, no. 1, 2022, p. 16.

  16. Al-Amery, A.K. et al. “Protective effect of ocimum tenuiflorum against negative effect of filgrastim on sperm parameters of male rats.” Revista Electrónica de Veterinaria, 2022, pp. 22–27.

  17. AbdulHussain, A.H. et al. “Ameliorative effect of the moringa pterygosperma extract against cyclophosphamide on the reproductive system.” Revista Electrónica de Veterinaria, 2022, pp. 77–84.

  18. Gati, M.A., and G.S.Bustani. “The effect of vitamin C pretreatment on acute nickel nephrotoxicity in male mice.” Revista Electrónica de Veterinaria, 2022, pp. 130–138.

Recommended Articles
Research Article
Amit Jain’s System of Practice: From Modern to Super Modern Diabetic Foot Surgery
Published: 11/12/2020
Download PDF
Research Article
Awareness Regarding Danger Sign and Symptoms During Pregnancy among Antenatal Mothers Attending Outpatient Department of Rural Hospital in Himachal Pradesh
Published: 26/05/2023
Download PDF
Research Article
Kidney Function’s Clinical Impacts on Covid-19 Infected Patients Who are on Β-Lactam Antibiotics
...
Published: 20/04/2023
Download PDF
Research Article
Curcumin: A Possible Treatment for Coronavirus Infection
Published: 10/10/2021
Download PDF
Chat on WhatsApp
Flowbite Logo
PO Box 101, Nakuru
Kenya.
Email: office@iarconsortium.org

Editorial Office:
J.L Bhavan, Near Radison Blu Hotel,
Jalukbari, Guwahati-India
Useful Links
Order Hard Copy
Privacy policy
Terms and Conditions
Refund Policy
Shipping Policy
Others
About Us
Team Members
Contact Us
Online Payments
Join as Editor
Join as Reviewer
Subscribe to our Newsletter
+91 60029-93949
Follow us
MOST SEARCHED KEYWORDS
Copyright © iARCON International LLP . All Rights Reserved.